The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful reduction in MG ...

Myasthenia gravis is an autoimmune condition that weakens the muscles in your body. Acetylcholine is a neurotransmitter that helps your muscles move. Most people with generalized myasthenia gravis ...

In healthy people, binding of the molecule acetylcholine (ACh) to its receptor (AChR) on skeletal muscle cells triggers muscle contraction underlying regular daily activities. In the autoimmune ...

In a serendipitous discovery, UC San Diego researchers using cryo-EM technology captured the first visualizations of the 3-D structure of the muscle acetylcholine receptor in fetal and adult muscles.

Decreased AChR-Ab titers correlated with improved myasthenia gravis symptoms, especially in ADL scores, within the first 3 months of treatment. The study found no baseline correlation between AChR-Ab ...

They discovered that these antibodies can disrupt the normal receptor functioning in a variety of ways. Certain antibodies block the regular acetylcholine binding process, the researchers found, while ...